Provectus Biopharmaceuticals, Inc. PXY.SG Stock
Provectus Biopharmaceuticals, Inc. Price Chart
Provectus Biopharmaceuticals, Inc. PXY.SG Financial and Trading Overview
Provectus Biopharmaceuticals, Inc. stock price | 0.05 EUR |
Previous Close | 0.08 EUR |
Open | 0.08 EUR |
Bid | 0.08 EUR x 500000 |
Ask | 0.13 EUR x 500000 |
Day's Range | 0.08 - 0.08 EUR |
52 Week Range | 0.03 - 0.17 EUR |
Volume | 0 EUR |
Avg. Volume | 416 EUR |
Market Cap | 44.32M EUR |
Beta (5Y Monthly) | 0.462676 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.01 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
PXY.SG Valuation Measures
Enterprise Value | 38.49M EUR |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 44.03961 |
Price/Book (mrq) | N/A |
Enterprise Value/Revenue | 38.247 |
Enterprise Value/EBITDA | -11.971 |
Trading Information
Provectus Biopharmaceuticals, Inc. Stock Price History
Beta (5Y Monthly) | 0.462676 |
52-Week Change | 137.50% |
S&P500 52-Week Change | 20.43% |
52 Week High | 0.17 EUR |
52 Week Low | 0.03 EUR |
50-Day Moving Average | 0.1 EUR |
200-Day Moving Average | 0.08 EUR |
PXY.SG Share Statistics
Avg. Volume (3 month) | 416 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 419.5M |
Float | 385.5M |
Short Ratio | N/A |
% Held by Insiders | 8.10% |
% Held by Institutions | 0.054% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -320.48% |
Gross Margin | -117.45% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -90.079% |
Return on Equity (ttm) | N/A |
Income Statement
Revenue (ttm) | 1.01M EUR |
Revenue Per Share (ttm) | 0.002 EUR |
Quarterly Revenue Growth (yoy) | 9.30% |
Gross Profit (ttm) | -1321320 EUR |
EBITDA | -3215702 EUR |
Net Income Avi to Common (ttm) | -3351215 EUR |
Diluted EPS (ttm) | -0.01 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 34.15K EUR |
Total Cash Per Share (mrq) | 0 EUR |
Total Debt (mrq) | 2.64M EUR |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 0.184 |
Book Value Per Share (mrq) | -0.017 |
Cash Flow Statement
Operating Cash Flow (ttm) | -3073363 EUR |
Levered Free Cash Flow (ttm) | -1196549 EUR |
Profile of Provectus Biopharmaceuticals, Inc.
Country | Germany |
State | TN |
City | Knoxville |
Address | 800 South Gay Street |
ZIP | 37929 |
Phone | 866 594 5999 |
Website | https://www.provectusbio.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 4 |
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis; and PV-305 for the treatment of infectious keratitis. The company is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, it develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections; as well as vertebrate development, wound healing, and tissue regrowth. The company has collaboration agreement with Bascom Palmer Eye Institute; and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.
Q&A For Provectus Biopharmaceuticals, Inc. Stock
What is a current PXY.SG stock price?
Provectus Biopharmaceuticals, Inc. PXY.SG stock price today per share is 0.05 EUR.
How to purchase Provectus Biopharmaceuticals, Inc. stock?
You can buy PXY.SG shares on the Stuttgart exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Provectus Biopharmaceuticals, Inc.?
The stock symbol or ticker of Provectus Biopharmaceuticals, Inc. is PXY.SG.
Which industry does the Provectus Biopharmaceuticals, Inc. company belong to?
The Provectus Biopharmaceuticals, Inc. industry is Biotechnology.
How many shares does Provectus Biopharmaceuticals, Inc. have in circulation?
The max supply of Provectus Biopharmaceuticals, Inc. shares is 1.28B.
What is Provectus Biopharmaceuticals, Inc. Price to Earnings Ratio (PE Ratio)?
Provectus Biopharmaceuticals, Inc. PE Ratio is now.
What was Provectus Biopharmaceuticals, Inc. earnings per share over the trailing 12 months (TTM)?
Provectus Biopharmaceuticals, Inc. EPS is -0.01 EUR over the trailing 12 months.
Which sector does the Provectus Biopharmaceuticals, Inc. company belong to?
The Provectus Biopharmaceuticals, Inc. sector is Healthcare.